Uncertainty around Russia could cause severe spike in oil, says Paul Sankey
Paul Sankey, lead analyst at Sankey Research, joins ‘The Exchange’ to discuss oil prices.
Similar Posts
Goldman downgrades key defense stocks to sell
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email CNBC’s Morgan Brennan joins ‘Power Lunch’ to report on Goldman Sachs’ sweeping downgrade of key stocks in the defense sector. 03:57 Fri, Jan 13 20232:43 PM EST
Goldman downgrades key defense stocks to sell
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email CNBC’s Morgan Brennan joins ‘Power Lunch’ to report on Goldman Sachs’ sweeping downgrade of key stocks in the defense sector. 03:57 Fri, Jan 13 20232:43 PM EST
CNBC PRO Talks: Morningstar’s chief U.S. strategist on stocks to beat the volatility
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Dave Sekera, chief U.S market strategist for Morningstar, joined CNBC’s Julianna Tatelbaum on Wednesday for a frank conversation on the market outlook. 33:50 Wed, Jul 13 20229:16 AM EDT
Watch CNBC’s full interview with Piper Sandler’s Michael Kantrowitz
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Power Lunch Michael Kantrowitz, chief investment strategist at Piper Sandler, joins ‘Power Lunch’ to discuss why he’s still bearish on the market and more. 06:36 12 minutes ago
AI is a wonderful sector to be in, says Matt Bryson of Wedbush Securities
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Matt Bryson of Wedbush Securities joins ‘TechCheck’ to discuss the swelling supply of semiconductors, bullish picks for the chip sector and the outlook for chip providers in gaming. 04:32 Tue, Dec 27 202212:08 PM EST
Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
